fda glp-1 safety warning september 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of ISPOR 2025: Exploring reasons for

Adjunct/Burden Support: Supportive therapies that do not directly stabilize mast cells but may reduce overall inflammatory, neurologic, or pain-related burden in complex cases

Ebrahimi-Mameghani, M., The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial

Patients who already have gastroesophageal reflux disease may notice worsening symptoms

Emerging competitors are advancing differentiated mechanisms beyond single GLP-1 agonism

Selenomethionone, 200mcg

GLP-1 medications work by slowing digestion, which helps regulate blood sugar and promote a feeling of fullness